Claims
- 1. A process for preparing a beta nucleoside anomer of the formula ##STR3## wherein R.sub.1 is hydroxy; R.sub.2 and R.sub.3 are each selected from the group consisting of hydrogen, azide, lower alkyl, fluoro, hydroxy, and OB provided when one of R.sub.2 and R.sub.3 is hydroxy, the other of R.sub.2 and R.sub.3 cannot be fluoro, azide or hydroxy; R.sub.4 and R.sub.5 are each selected from the group consisting of hydrogen, azide, lower alkyl, fluoro, hydroxy, and OB, where each B is independently a lower alkyl or base-stable hydroxyl protecting group; provided when one of R.sub.4 and R.sub.5 is hydroxy, the other of R.sub.4 and R.sub.5 cannot be fluoro, azide or hydroxy; and Z is a nucleobase of the formula ##STR4## wherein X is selected from N and CR.sub.8 where R.sub.8 is hydrogen or lower alkyl; R.sub.6 is selected from the group consisting of amino, lower alkyl amino, di(lower alkyl) amino, acyl amino, and N-acyl lower alkyl amino; and R.sub.7 is selected from the group consisting of hydrogen, lower alkyl, fluoro and lower alkenyl; comprising contacting an alpha nucleoside of formula ##STR5## with a hydroxide base in an organic solvent.
- 2. The process of claim 1 wherein the hydroxide base is selected from the group consisting of alkali metal hydroxides, alkaline earth metal hydroxides or quaternary ammonium hydroxides.
- 3. The process of claim 2 wherein the hydroxide base is an alkali metal hydroxide selected from the group consisting of lithium hydroxide, potassium hydroxide, cesium hydroxide monohydrate or sodium hydroxide or an alkaline earth metal hydroxide such as barium hydroxide.
- 4. The process of claim 3 wherein the alkali metal hydroxide is selected from potassium hydroxide, sodium hydroxide or cesium hydroxide monohydrate.
- 5. The process of claim 4 wherein the alkali metal hydroxide is selected from potassium hydroxide or cesium hydroxide monohydrate.
- 6. The process of claim 1 wherein the amount of hydroxide base is from about 2 molar equivalents to about 40 molar equivalents.
- 7. The process of claim 6 wherein the amount of hydroxide base is from about 2.5 molar equivalents to about 5 molar equivalents.
- 8. The process of claim 1 wherein the hydroxide base concentration is from about 0.5 molar to about 5 molar.
- 9. The process of claim 8 wherein the hydroxide base concentration is from about 2 molar to about 4 molar.
- 10. The process of claim 1 wherein the solvent is selected from methanol, ethanol, 2-methoxyethanol, and mixtures thereof.
- 11. The process of claim 10 wherein the solvent is methanol.
- 12. The process of claim 10 wherein the solvent is a substantially anhydrous organic solvent.
- 13. The process of claim 1 wherein the process temperature is from room temperature to about 120.degree. C.
- 14. The process of claim 13 wherein the process temperature is from about 40.degree. C. to about 120.degree. C.
- 15. The process of claim 14 wherein the process temperature is from about 40.degree. C. to about 80.degree. C.
- 16. The process of claim 1 wherein 1-(2'-deoxy-2',2'-difluoro-.alpha.-D-ribofuranosyl)-4-aminopyrimidin-2-one is contacted with anhydrous lithium hydroxide in methanol to form 1-(2'-deoxy-2',2'-difluoro-.beta.-D-ribofuranosyl)-4-aminopyrimidin-2-one.
- 17. The process of claim 1 wherein of 1-(2'-deoxy-2',2'-difluoro-.alpha.-D-ribofuranosyl)-4-aminopyrimidin-2-one is contacted with anhydrous sodium hydroxide in methanol to form 1-(2'-deoxy-2',2'-difluoro-.beta.-D-ribofuranosyl)-4-aminopyrimidin-2-one.
- 18. The process of claim 1 wherein 1-(2'-deoxy-2',2'-difluoro-.alpha.-D-ribofuranosyl)-4-aminopyrimidin-2-one is contacted with potassium hydroxide in ethanol to form 1-(2'-deoxy-2',2'-difluoro-.beta.-D-ribofuranosyl)-4-aminopyrimidin-2-one.
- 19. The process of claim 1 wherein 1-(2'-deoxy-2',2'-difluoro-.alpha.-D-ribofuranosyl)-4-aminopyrimidin-2-one is contacted with barium hydroxide in methanol to form 1-(2'-deoxy-2',2'-difluoro-.beta.-D-ribofuranosyl)-4-aminopyrimidin-2-one.
- 20. The process of claim 1 wherein 1-(2'-deoxy-2',2'-difluoro-.alpha.-D-ribofuranosyl)-4-aminopyrimidin-2-one is contacted with cesium hydroxide monohydrate in methanol to form 1-(2'-deoxy-2',2'-difluoro-.beta.-D-ribofuranosyl)-4-aminopyrimidin-2-one.
- 21. The process of claim 1 wherein 1-(2'-deoxy-2',2'-difluoro-.alpha.-D-ribofuranosyl)-4-aminopyrimidin-2-one is contacted with potassium hydroxide in 2-methoxyethanol to form 1-(2'-deoxy-2',2'-difluoro-.beta.-D-ribofuranosyl)-4-aminopyrimidin-2-one.
- 22. The process of claim 1 wherein 1-(2'-deoxy-2',2'-difluoro-.alpha.-D-ribofuranosyl)-4-aminopyrimidin-2-one is contacted with potassium hydroxide in methanol to form 1-(2'-deoxy-2',2'-difluoro-.beta.-D-ribofuranosyl)-4-aminopyrimidin-2-one.
- 23. The process of claim 1 wherein 1-(2'-deoxy-2',2'-difluoro-.alpha.-D-ribofuranosyl)-4-aminopyrimidin-2-one is contacted with potassium hydroxide in methanol to form 1-(2'-deoxy-2',2'-difluoro-.beta.-D-ribofuranosyl)-4-aminopyrimidin-2-one.
- 24. The process of claim 1 wherein 1-(2'-deoxy-2',2'-difluoro-.alpha.-D-ribofuranosyl)-4-aminopyrimidin-2-one is contacted with benzyltrimethylammonium hydroxide in methanol to form 1-(2'-deoxy-2',2'-difluoro-.beta.-D-ribofuranosyl)-4-aminopyrimidin-2-one.
- 25. The process of claim 1 wherein an 81:19 alpha to beta mixture of 1-(2'-deoxy-2',2'-difluoro-D-ribofuranosyl)-4-aminopyrimidin-2-one is contacted with potassium hydroxide in methanol to form 1-(2'-deoxy-2',2'-difluoro-.beta.-D-ribofuranosyl)-4-aminopyrimidin-2-one.
- 26. The process of claim 1 wherein 1-(2'-deoxy-.alpha.-D-ribofuranosyl)-4-aminopyrimidin-2-one is contacted with potassium hydroxide in methanol to form 1-(2'-deoxy-.beta.-D-ribofuranosyl)-4-aminopyrimidin-2-one.
- 27. A process for preparing an alpha nucleoside anomer of the formula ##STR6## wherein R.sub.1 is hydroxy; R.sub.2 and R.sub.3 are each selected from the group consisting of hydrogen, azide, lower alkyl, fluoro, hydroxy, and OB provided when one of R.sub.2 and R.sub.3 is hydroxy, the other of R.sub.2 and R.sub.3 cannot be fluoro, azide or hydroxy; R.sub.4 and R.sub.5 are each selected from the group consisting of hydrogen, azide, lower alkyl, fluoro, hydroxy, and OB, where each B is independently a lower alkyl or base-stable hydroxyl protecting group; provided when one of R.sub.4 and R.sub.5 is hydroxy, the other of R.sub.4 and R5 cannot be fluoro, azide or hydroxy; and Z is a nucleobase of the formula ##STR7## wherein X is selected from N and CR.sub.8 where R.sub.8 is hydrogen or lower alkyl; R.sub.6 is selected from the group consisting of amino, lower alkyl amino, di(lower alkyl) amino, acyl amino, and N-acyl lower alkyl amino; and R.sub.7 is selected from the group consisting of hydrogen, lower alkyl, fluoro and lower alkenyl; comprising contacting a beta nucleoside of formula ##STR8## with a hydroxide base in an organic solvent.
- 28. The process of claim 27 wherein the hydroxide base is selected from the group consisting of alkali metal hydroxides, alkaline earth metal hydroxides or quaternary ammonium hydroxides.
- 29. The process of claim 28 wherein the hydroxide base is an alkali metal hydroxide selected from the group consisting of lithium hydroxide, potassium hydroxide, cesium hydroxide monohydrate or sodium hydroxide or an alkaline earth metal hydroxide such as barium hydroxide.
- 30. The process of claim 29 wherein the alkali metal hydroxide is selected from potassium hydroxide, sodium hydroxide or cesium hydroxide monohydrate.
- 31. The process of claim 30 wherein the alkali metal hydroxide is selected from potassium hydroxide or cesium hydroxide monohydrate.
- 32. The process of claim 27 wherein the amount of hydroxide base is from about 2 molar equivalents to about 40 molar equivalents.
- 33. The process of claim 32 wherein the amount of hydroxide base is from about 2.5 molar equivalents to about 5 molar equivalents.
- 34. The process of claim 27 wherein the hydroxide base concentration is from about 0.5 molar to about 5 molar.
- 35. The process of claim 34 wherein the hydroxide base concentration is from about 2 molar to about 4 molar.
- 36. The process of claim 27 wherein the solvent is selected from methanol, ethanol, 2-methoxyethanol, and mixtures thereof.
- 37. The process of claim 36 wherein the solvent is methanol.
- 38. The process of claim 27 wherein the solvent is a substantially anhydrous organic solvent.
- 39. The process of claim 27 wherein the process temperature is from room temperature to about 120.degree. C.
- 40. The process of claim 39 wherein the process temperature is from about 40.degree. C. to about 120.degree. C.
- 41. The process of claim 40 wherein the process temperature is from about 40.degree. C. to about 80.degree. C.
- 42. The process of claim 27 wherein 1-(2'-deoxy-2',2'-difluoro-.beta.-D-ribofuranosyl)-4-aminopyrimidin-2-one is contacted with potassium hydroxide in methanol to form 1-(2'-deoxy-2',2'-difluoro-.alpha.-D-ribofuranosyl)-4-aminopyrimidin-2-one
- 43. The process of claim 27 wherein 1-(.beta.-D-ribofuranosyl)-4-aminopyrimidin-2-one is contacted with potassium hydroxide in methanol to form 1-(.alpha.-D-ribofuranosyl)-4-aminopyrimidin-2-one
Parent Case Info
This application is a continuation of application Ser. No. 07/938,791, filed on Sep. 1, 1992, now abandoned.
Non-Patent Literature Citations (2)
| Entry |
| Armstrong et al., Nucleic Acid Research, vol. 3, No. 7, pp. 1791-1810, (1976). |
| Inoue et al., Heterocycles, vol. 8, pp. 427-432 (1977). |
Continuations (1)
|
Number |
Date |
Country |
| Parent |
938791 |
Sep 1992 |
|